Ost-müük Spero Therapeutics, Inc. - SPRO CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Hinnavahe | - | ||||||||
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.024874% | ||||||||
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | 0.002651% | ||||||||
Ööpäeva tasu aeg | 21:00 (UTC) | ||||||||
Min kauplemise kogus | 1 | ||||||||
Valuuta | USD | ||||||||
Tagatis | 20% | ||||||||
Aktsiabörs | United States of America | ||||||||
Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
Eelmine sulgemine* | N/A |
Avatud* | N/A |
Aastane muutus* | N/A |
Päeva ulatus* | N/A |
52 nädala ulatus | 0.68-8.79 |
Keskmine maht (10 päeva) | 549.01K |
Keskmine maht (3 kuud) | 8.96M |
Turukapitalisatsioon | 74.56M |
P/E suhtarv | -100.00K |
Ringluses olevad aktsiad | 51.78M |
Tulu | 8.81M |
EPS | -3.11 |
Dividendid (% kasumist) | N/A |
Beeta | 0.88 |
Järgmine tuluaruande kuupäev | May 15, 2023 |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
---|
Spero Therapeutics, Inc. Events
Kellaaeg (UTC) (UTC) | Riik | Sündmus |
---|---|---|
No events scheduled |
- Aastas
- Kvartalis
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Kogutulu | 18.256 | 9.33 | 18.147 | 3.966 | 1.979 |
Tulu | 18.256 | 9.33 | 18.147 | 3.966 | 1.979 |
Kogu tegevuskulu | 106.227 | 88.443 | 81.363 | 46.772 | 43.709 |
Müük/Üldine/admin kulud, kokku | 41.701 | 21.44 | 15.588 | 12.887 | 10.84 |
Uuringud ja arendus | 64.526 | 67.003 | 65.775 | 33.885 | 32.869 |
Tulud majandustegevusest | -87.971 | -79.113 | -63.216 | -42.806 | -41.73 |
Intressitulud (kulu), muud tulud, neto | -1.39 | 0.401 | 1.551 | 0 | 1.541 |
Muud, neto | -0.395 | 0.432 | 0.74 | 1.144 | 0.303 |
Netotulu enne makse | -89.756 | -78.28 | -60.925 | -41.662 | -39.886 |
Netotulu pärast makse | -89.756 | -78.28 | -60.925 | -41.662 | -39.886 |
Vähemuse intress | 0 | 1.143 | |||
Netotulu enne erikulusid | -89.756 | -78.28 | -60.925 | -41.662 | -38.743 |
Netotulu | -89.756 | -78.28 | -60.925 | -41.662 | -38.743 |
Total Adjustments to Net Income | 0 | -0.549 | 0 | -7.354 | |
Arvestatav tulu, v a erikulud | -89.756 | -78.829 | -60.925 | -41.662 | -46.097 |
Arvestatav tulu, koos erikuludega | -89.756 | -78.829 | -60.925 | -41.662 | -46.097 |
Jaotuse korrigeerimine | |||||
Jaotamisele kuuluv netotulu | -89.756 | -78.829 | -60.925 | -41.662 | -46.097 |
Keskmine jaotamisele kuuluv aktsia kohta | 30.8958 | 22.3861 | 18.1605 | 16.0018 | 14.3692 |
Jaotatav EPS, v a erakorralised kulud | -2.90512 | -3.52133 | -3.3548 | -2.60358 | -3.20805 |
Dividends per Share - Common Stock Primary Issue | |||||
Jaotamisele kuuluv normaal-EPS | -2.90512 | -3.52133 | -3.3548 | -2.60358 | -3.20805 |
Erakorralised kulud kokku | 0 | 0 |
Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | |
---|---|---|---|---|---|
Kogutulu | 2.006 | 1.993 | 2.069 | 2.744 | 3.064 |
Tulu | 2.006 | 1.993 | 2.069 | 2.744 | 3.064 |
Kogu tegevuskulu | 13.84 | 31.654 | 32.276 | 30.246 | 25.588 |
Müük/Üldine/admin kulud, kokku | 6.632 | 8.051 | 15.305 | 13.021 | 11.152 |
Uuringud ja arendus | 7.36 | 8.173 | 16.971 | 17.225 | 14.436 |
Tulud majandustegevusest | -11.834 | -29.661 | -30.207 | -27.502 | -22.524 |
Intressitulud (kulu), muud tulud, neto | 0.182 | 0.989 | -2.609 | -1.66 | 0.09 |
Muud, neto | -0.023 | -0.01 | -0.013 | -0.078 | -0.087 |
Netotulu enne makse | -11.675 | -28.682 | -32.829 | -29.24 | -22.521 |
Netotulu pärast makse | -11.675 | -28.682 | -32.829 | -29.24 | -22.521 |
Netotulu enne erikulusid | -11.675 | -28.682 | -32.829 | -29.24 | -22.521 |
Netotulu | -11.675 | -28.682 | -32.829 | -29.24 | -22.521 |
Arvestatav tulu, v a erikulud | -11.675 | -28.682 | -32.829 | -29.24 | -22.521 |
Arvestatav tulu, koos erikuludega | -11.675 | -28.682 | -32.829 | -29.24 | -22.521 |
Jaotamisele kuuluv netotulu | -11.675 | -28.682 | -32.829 | -29.24 | -22.521 |
Keskmine jaotamisele kuuluv aktsia kohta | 35.8821 | 32.9778 | 32.6067 | 32.3311 | 32.1325 |
Jaotatav EPS, v a erakorralised kulud | -0.32537 | -0.86974 | -1.00682 | -0.90439 | -0.70088 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Jaotamisele kuuluv normaal-EPS | -0.32961 | -0.40185 | -1.00682 | -0.90439 | -0.70088 |
Total Adjustments to Net Income | 0 | 0 | |||
Ootamatud kulutused (tulu) | -0.152 | 15.43 |
- Aastas
- Kvartalis
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Käibevarad kokku | 157.872 | 139.145 | 95.414 | 124.219 | 92.059 |
Raha ja lühiajalised investeeringud | 146.402 | 126.906 | 82.045 | 115.443 | 87.288 |
Raha ja ekvivalendid | 112.584 | 85.209 | 29.73 | 34.08 | 87.288 |
Laekumata arved, neto | 2.641 | 6.176 | 8.546 | 1.298 | 2.943 |
Prepaid Expenses | 8.829 | 6.063 | 4.823 | 7.478 | 1.828 |
Total Assets | 171.072 | 153.451 | 106.103 | 129.006 | 93.479 |
Property/Plant/Equipment, Total - Net | 7.556 | 8.783 | 7.148 | 2.893 | 1.164 |
Property/Plant/Equipment, Total - Gross | 10.436 | 11.059 | 8.663 | 3.72 | 1.807 |
Accumulated Depreciation, Total | -2.88 | -2.276 | -1.515 | -0.827 | -0.643 |
Note Receivable - Long Term | 0 | 0.311 | 0.021 | 0.233 | 0 |
Other Long Term Assets, Total | 5.644 | 5.212 | 3.52 | 1.661 | 0.256 |
Total Current Liabilities | 18.67 | 14.343 | 26.663 | 12.318 | 8.157 |
Accounts Payable | 1.101 | 1.155 | 4.147 | 3.603 | 3.47 |
Accrued Expenses | 15.712 | 13.188 | 22.516 | 8.263 | 4.321 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 1.857 | 0 | 0.452 | 0.366 | |
Total Liabilities | 82.783 | 21.411 | 31.529 | 13.506 | 8.877 |
Total Long Term Debt | 48.414 | 0 | 0 | 0 | 0 |
Minority Interest | 0.355 | 0.355 | |||
Other Liabilities, Total | 15.699 | 7.068 | 4.866 | 0.833 | 0.365 |
Total Equity | 88.289 | 132.04 | 74.574 | 115.5 | 84.602 |
Redeemable Preferred Stock | 0 | 0 | |||
Common Stock | 0.032 | 0.029 | 0.019 | 0.017 | 0.014 |
Additional Paid-In Capital | 455.719 | 409.722 | 273.966 | 254.013 | 181.428 |
Retained Earnings (Accumulated Deficit) | -367.463 | -277.707 | -199.427 | -138.502 | -96.84 |
Total Liabilities & Shareholders’ Equity | 171.072 | 153.451 | 106.103 | 129.006 | 93.479 |
Total Common Shares Outstanding | 32.3937 | 29.2603 | 19.1907 | 17.206 | 14.3692 |
Lühiajalised investeeringud | 33.818 | 41.697 | 52.315 | 81.363 | |
Other Equity, Total | -0.002 | -0.007 | 0.016 | -0.028 | |
Preferred Stock - Non Redeemable, Net | 0.003 | 0.003 | |||
Total Preferred Shares Outstanding | 3.21815 | 3.21829 | |||
Long Term Debt | 48.414 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Käibevarad kokku | 132.704 | 157.872 | 131.769 | 106.316 | 129.492 |
Raha ja lühiajalised investeeringud | 121.966 | 146.402 | 123.417 | 99.218 | 115.676 |
Raha ja ekvivalendid | 72.111 | 112.584 | 112.859 | 71.562 | 77.042 |
Lühiajalised investeeringud | 49.855 | 33.818 | 10.558 | 27.656 | 38.634 |
Laekumata arved, neto | 1.991 | 2.641 | 2.584 | 2.197 | 8.622 |
Prepaid Expenses | 8.747 | 8.829 | 5.768 | 4.901 | 5.194 |
Total Assets | 145.83 | 171.072 | 144.691 | 119.594 | 143.44 |
Property/Plant/Equipment, Total - Net | 7.197 | 7.556 | 7.71 | 8.067 | 8.425 |
Note Receivable - Long Term | 0 | 0 | 0 | 0.311 | |
Other Long Term Assets, Total | 5.929 | 5.644 | 5.212 | 5.211 | 5.212 |
Total Current Liabilities | 69.199 | 18.67 | 17.258 | 12.826 | 17.763 |
Accounts Payable | 4.78 | 1.101 | 3.161 | 1.632 | 3.825 |
Accrued Expenses | 10.429 | 15.712 | 12.398 | 10.015 | 13.938 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 83.357 | 82.783 | 32.796 | 29.342 | 24.594 |
Total Long Term Debt | 0 | 48.414 | 0 | 0 | 0 |
Other Liabilities, Total | 14.158 | 15.699 | 15.538 | 16.516 | 6.831 |
Total Equity | 62.473 | 88.289 | 111.895 | 90.252 | 118.846 |
Preferred Stock - Non Redeemable, Net | 0.003 | 0.003 | 0.003 | 0.003 | 0.003 |
Common Stock | 0.033 | 0.032 | 0.032 | 0.03 | 0.03 |
Additional Paid-In Capital | 462.735 | 455.719 | 450.085 | 405.923 | 415.946 |
Retained Earnings (Accumulated Deficit) | -400.292 | -367.463 | -338.223 | -315.702 | -297.13 |
Other Equity, Total | -0.006 | -0.002 | -0.002 | -0.002 | -0.003 |
Total Liabilities & Shareholders’ Equity | 145.83 | 171.072 | 144.691 | 119.594 | 143.44 |
Total Common Shares Outstanding | 32.7556 | 32.3937 | 32.2203 | 29.6992 | 29.6639 |
Total Preferred Shares Outstanding | 3.21815 | 3.21815 | 3.21815 | 3.21815 | 3.21815 |
Other Current Liabilities, Total | 53.99 | 1.857 | 1.699 | 1.179 | |
Long Term Debt | 0 | 48.414 |
- Aastas
- Kvartalis
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Netotulu/algväärtus | -89.756 | -78.28 | -60.925 | -41.662 | -39.886 |
Raha majandustegevusest | -64.347 | -85.872 | -50.02 | -39.625 | -39.111 |
Raha majandustegevusest | 0.646 | 0.761 | 0.75 | 0.409 | 0.363 |
Mittelikviidsed varad | 11.901 | 5.111 | 3.376 | 2.699 | -0.031 |
Muutused tööjõus | 12.862 | -13.464 | 6.779 | -1.071 | 0.443 |
Tulu investeeringutelt | 7.672 | 10.47 | 29.53 | -83.156 | -0.027 |
Kapitalikulutused | -0.157 | -0.314 | -2.436 | -0.027 | |
Rahavood investeeringutelt | 84.05 | 130.881 | 16.14 | 69.523 | 116.111 |
Rahavoogudesse investeerimine | 47.232 | -0.953 | -0.158 | -1.312 | -4.749 |
Aktsiate emiteerimine (tagasiost), neto | 36.818 | 131.834 | 16.298 | 70.835 | 120.86 |
Rahaline kogumuutus | 27.375 | 55.479 | -4.35 | -53.258 | 76.973 |
Muud rahavood investeeringutelt, kokku | 7.672 | 10.627 | 29.844 | -80.72 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -32.829 | -89.756 | -60.516 | -37.995 | -19.423 |
Cash From Operating Activities | -28.223 | -64.347 | -36.998 | -32.046 | -15.479 |
Cash From Operating Activities | 0.189 | 0.646 | 0.455 | 0.307 | 0.159 |
Non-Cash Items | 6.117 | 11.901 | 7.327 | 4.708 | 2.253 |
Changes in Working Capital | -1.7 | 12.862 | 15.736 | 0.934 | 1.532 |
Cash From Investing Activities | -16.064 | 7.672 | 30.947 | 13.922 | 3.003 |
Other Investing Cash Flow Items, Total | -16.064 | 7.672 | 30.947 | 13.922 | 3.003 |
Cash From Financing Activities | 3.814 | 84.05 | 33.701 | 4.477 | 4.309 |
Financing Cash Flow Items | 0 | 47.232 | -0.411 | -0.146 | -0.037 |
Issuance (Retirement) of Stock, Net | 3.814 | 36.818 | 34.112 | 4.623 | 4.346 |
Net Change in Cash | -40.473 | 27.375 | 27.65 | -13.647 | -8.167 |
Capital Expenditures | 0 | 0 |
Investori nimi | Investori liik | Ringluse protsent | Hoitud osakud | Muutus osakutes | Hoidmise kuupäev | Hinnang käibele |
---|---|---|---|---|---|---|
GSK plc | Corporation | 17.7507 | 9190606 | 7450000 | 2022-11-14 | MED |
Anson Funds Management LP. | Hedge Fund | 5.8321 | 3019608 | 1545736 | 2022-12-31 | HIGH |
Atlas Venture | Venture Capital | 4.651 | 2408128 | 0 | 2022-12-31 | LOW |
Pfizer Inc | Corporation | 4.5626 | 2362348 | 0 | 2022-07-20 | MED |
AWM Investment Company, Inc. | Investment Advisor/Hedge Fund | 2.5116 | 1300400 | -1000000 | 2022-12-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.0364 | 1054388 | 665 | 2022-12-31 | LOW |
Alphabet, Inc. | Venture Capital | 1.7189 | 889979 | 0 | 2022-12-31 | LOW |
Millennium Management LLC | Hedge Fund | 1.6927 | 876398 | 188002 | 2022-12-31 | HIGH |
Murchinson Ltd. | Investment Advisor/Hedge Fund | 1.4731 | 762700 | 0 | 2022-12-31 | HIGH |
Rock Springs Capital Management LP | Hedge Fund | 1.2931 | 669533 | -101177 | 2022-12-31 | LOW |
Mahadevia (Ankit) | Individual Investor | 1.1307 | 585445 | 519628 | 2023-02-03 | MED |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.9252 | 479031 | -187473 | 2022-12-31 | LOW |
Hamed (Kamal) | Individual Investor | 0.9193 | 475957 | 265957 | 2023-02-01 | MED |
Novo Holdings A/S | Venture Capital | 0.9056 | 468902 | 0 | 2022-12-31 | LOW |
XTX Markets LLC | Investment Advisor | 0.6697 | 346734 | 346734 | 2022-12-31 | HIGH |
Renaissance Technologies LLC | Hedge Fund | 0.6623 | 342900 | 128200 | 2022-12-31 | HIGH |
Keutzer (Timothy) | Individual Investor | 0.6318 | 327144 | 262563 | 2023-02-02 | LOW |
Joseph (Tamara) | Individual Investor | 0.627 | 324644 | 262563 | 2023-02-02 | LOW |
Oasis Management Company Ltd. | Investment Advisor/Hedge Fund | 0.5562 | 288000 | 0 | 2022-12-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.4969 | 257284 | -32974 | 2022-12-31 | LOW |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com Group500K+
Kauplejad
92K+
Igakuiste aktiivsete klientide arv
$53M+
Igakuine investeerimise maht
$30M+
Igakuiselt välja võetud
Kauplemiskalkulaator
Arvutage oma hüpoteetiline võit/kaotus, kui oleksite avanud CFD-tehingu ühel kindlal kuupäeval (valige kuupäev) ja sulgenud teisel kuupäeval (valige kuupäev).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Spero Therapeutics, Inc. Company profile
Ettevõttest Spero Therapeutics, Inc.
Spero Therapeutics, Inc. on kliinilise faasi biofarmatseutiline ettevõte. Ettevõte keskendub MDR-bakteriaalsete infektsioonide uudsete ravimeetodite tuvastamisele, arendamisele ja turustamisele. Ettevõtte juhtiv tootekandidaat, tebipeneem HBr (tebipeneem pivoksiilhüdrobromiid), on välja töötatud suukaudse karbapeneemantibiootikumina kasutamiseks komplitseeritud kuseteede infektsioonide (cUTI) ja ägeda püelonefriidi (AP) korral. Samuti arendab ta SPR720 kui uudset suukaudset ravimikandidaati harvaesinevate, harvaesinevate kopsuhaiguste raviks, mida põhjustavad mittetuberkuloossed mükobakteriaalsed (NTM) infektsioonid. Ettevõttel on ka järgmise põlvkonna polümüksiini tootekandidaat SPR206, mis on välja töötatud tema potentsiatoriplatvormi alusel ja mida arendatakse MDR gramnegatiivsete infektsioonide raviks haiglas.
Industry: | Bio Therapeutic Drugs |
675 Massachusetts Ave Ste 14
CAMBRIDGE
MASSACHUSETTS 02139-3309
US
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 500,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com